CD70 and myelodysplastic syndrome: However, further validation is required and we are currently planning a prospective, flow cytometry-based analysis to confirm the diagnostic and prognostic utility of our immune-related biomarkers (including PD-L2, CD47, CD70 and TIM3) in a much larger cohort of patients with unclear cytopenia, MDS and related disorders.